



16 January 2019

ASX ANNOUNCEMENT

ImpediMed Receives Ascension National Purchasing Agreement

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced it has received a multi-year national purchasing agreement for its SOZO® Digital Health Platform from Ascension Health Resources.

This agreement allows the 151 Ascension hospitals to take advantage of pre-negotiated pricing and streamlined IT integration of the SOZO platform. Ascension is the largest non-profit health system in the US and the largest Catholic health system in the world.

Richard Carreon, Managing Director and CEO of ImpediMed said “We’re extremely pleased to be able to expedite the integration of SOZO for any Ascension facility wishing to adopt SOZO into their practice, and honoured to be pre-approved by the Ascension Health Resource and Supply Management Group. We look forward to continuing the commitment of both organisations to delivering compassionate, personalised care to all cancer survivors.”

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing

bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.